高盛:药明康德(02359)上季盈利胜预期 关注新订单动能与临床CRO业务 目标价109.6港元
智通财经网·2025-10-28 07:18

Core Viewpoint - Goldman Sachs anticipates a positive market reaction to WuXi AppTec's strong performance and new order momentum, despite concerns regarding the slowdown in TIDES order reserve growth [1] Financial Performance - WuXi AppTec reported third-quarter revenue of 12.1 billion RMB, representing a year-on-year increase of 15.3%, or a 19.7% increase when considering continuing operations [1] - The TIDES business experienced a significant year-on-year growth of 91%, contributing to 23% of total revenue [1] Price Target and Valuation - Goldman Sachs set a 12-month price target of 109.6 HKD for WuXi AppTec's Hong Kong stock, based on a forward P/E ratio of 18 times, while the target price for its Shanghai stock is set at 105.6 RMB [1] Revenue Guidance - The management of WuXi AppTec raised its full-year revenue guidance for 2025 to 43.5 to 44 billion RMB, up from the previous guidance of 42.5 to 43.5 billion RMB [1] - The revenue growth guidance for continuing operations was also increased to 17% to 18% year-on-year, compared to the previous range of 13% to 17% [1] Profitability and Capital Expenditure - The adjusted net profit margin is expected to improve [1] - Third-quarter capital expenditures amounted to 1.47 billion RMB, with a total of 3.57 billion RMB for the first nine months [1] - The full-year capital expenditure budget has been revised down to 5.5 to 6 billion RMB from the previous estimate of 7 to 8 billion RMB due to longer-than-expected settlement periods for some projects [1] - Free cash flow guidance has been raised to 8 to 8.5 billion RMB, up from the previous range of 5 to 6 billion RMB [1] - Management reiterated its commitment to advancing global capacity construction [1]

WuXi AppTec-高盛:药明康德(02359)上季盈利胜预期 关注新订单动能与临床CRO业务 目标价109.6港元 - Reportify